On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical data disclosure.

On the news front, the company's wholly-owned subsidiary Leads Biolabs Inc. received written notice from Oblenio Bio, Inc. formally exercising its exclusive option to retain the global development, manufacturing, and commercialization license for LBL-051. Under the agreement signed in November 2024, Oblenio will pay a one-time, non-refundable and non-creditable fee of US$10 million. The company views the option exercise as a significant collaboration milestone that lays the groundwork for LBL-051's global clinical development and commercialization.

Simultaneously, the company announced that the Phase II clinical study abstract for its core product Welixin (opamtistomig, PD-L1/4-1BB bispecific antibody, LBL-024) as first-line treatment for NSCLC was published on the WCLC official website, adding further visibility to its pipeline progress ahead of the upcoming mid-term results review scheduled for August 31.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)